112 assets in Nonpapillary Renal Cell Carcinoma

Therapeutic assets addressing Nonpapillary Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Xmab819 Nonpapillary Renal Cell Carcinoma	Xencor, Inc.	P1	C (39)
Zimberelimab Nonpapillary Renal Cell Carcinoma	Arcus Biosciences, Inc.	P1	C (39)
Ksd-201 Nonpapillary Renal Cell Carcinoma	Kousai Bio Co., Ltd.	Early P1	C (38)
68Ga-C1 Nonpapillary Renal Cell Carcinoma	Peking University First Hospital	N/A	D (30)
68ga-p16-093 Nonpapillary Renal Cell Carcinoma	Peking Union Medical College Hospital	N/A	D (30)
Fludeoxyglucose Nonpapillary Renal Cell Carcinoma	Peking Union Medical College Hospital	N/A	D (30)
Temferon Nonpapillary Renal Cell Carcinoma	Genenta Science	P1/2	D (26)
cgc738 Nonpapillary Renal Cell Carcinoma	RenJi Hospital	P1	NR ()
Ib-T101 Nonpapillary Renal Cell Carcinoma	Grit Biotechnology	P1	NR ()
lnk001 Nonpapillary Renal Cell Carcinoma	M.D. Anderson Cancer Center	P1	NR ()
ucb4594 Nonpapillary Renal Cell Carcinoma	Cancer Research UK	P1/2	NR ()
ucl70805f Nonpapillary Renal Cell Carcinoma	UTC Therapeutics Inc.	P1	NR ()

Showing 101 to 112 of 112 assets

PreviousPage 3 of 3Next